Zhongheng Group announced that its holding subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” for injectable esomeprazole sodium (specification: 20 mg) approved and issued by the State Drug Administration.
中恒集团：控股子公司获得注射用艾司奥美拉唑钠补充申请批准通知书
Zhongheng Group: The holding subsidiary received a notice of approval for injectable esomeprazole sodium supplementation
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.